Q17 Classify the calcium channel blockers and
... hypotension. In patients without CCF can improve cardiac function by improving ischaemia. In patients with CCF can make LV function worse (because it reduces myocardial contractility). Contraindicated in patients ...
... hypotension. In patients without CCF can improve cardiac function by improving ischaemia. In patients with CCF can make LV function worse (because it reduces myocardial contractility). Contraindicated in patients ...
highlights - Graef Lab
... Drugs that target key enzymes in the life cycle of human immunodeficiency virus (HIV) have revolutionized the treatment of HIV in the past decade. Nevertheless, drug resistance remains a major problem. Writing in Chemistry and Biology, Schiffer and colleagues propose a novel structure-based strategy ...
... Drugs that target key enzymes in the life cycle of human immunodeficiency virus (HIV) have revolutionized the treatment of HIV in the past decade. Nevertheless, drug resistance remains a major problem. Writing in Chemistry and Biology, Schiffer and colleagues propose a novel structure-based strategy ...
anticoagulantpresent..
... clotting Factors its contact in vitro with glass or highly charged surfaces. • Intrinsic and extrinsic activation of the coagulation cascade leads to the generation of thrombin, the activation of fibrinogen, the release of fibrinopeptides, the formation of soluble fibrin, and finally, the formation ...
... clotting Factors its contact in vitro with glass or highly charged surfaces. • Intrinsic and extrinsic activation of the coagulation cascade leads to the generation of thrombin, the activation of fibrinogen, the release of fibrinopeptides, the formation of soluble fibrin, and finally, the formation ...
ANTICOAGULANT
... – Not rapid, but lasts 1-2 weeks. Do not use if wishing to restart warfarin within next week. In some cases only stopping the drug can be enough ...
... – Not rapid, but lasts 1-2 weeks. Do not use if wishing to restart warfarin within next week. In some cases only stopping the drug can be enough ...
savaysa
... have not been established. • Patients with DVT and/or PE and body weight ≤60 kg, reduce dose to 30mg ...
... have not been established. • Patients with DVT and/or PE and body weight ≤60 kg, reduce dose to 30mg ...
Topic 1 Organic Structures and Interactions of Drugs
... the cell, preventing the passage of water and polar molecules ...
... the cell, preventing the passage of water and polar molecules ...
Plasma Protein Binding
... intraperitoneal, intramuscular, subcutaneous, transdermal, transfer drug ...
... intraperitoneal, intramuscular, subcutaneous, transdermal, transfer drug ...
Anti-Ulcer Agents
... antihistamines fail to inhibit other actions of histamine? The possibility of a second histamine receptor … ...
... antihistamines fail to inhibit other actions of histamine? The possibility of a second histamine receptor … ...
the Presentation - Alabama Pharmacy Association
... reduction secondary to afib. B. Dabigatran can be used in patients on hemo‐ or peritoneal diaylsis C. Dabigatran is now approved post hip and knee replacement in the US D. Dabigatran can be started after the completion of 5‐10days UFH/LMWH therapy in acute VTE ...
... reduction secondary to afib. B. Dabigatran can be used in patients on hemo‐ or peritoneal diaylsis C. Dabigatran is now approved post hip and knee replacement in the US D. Dabigatran can be started after the completion of 5‐10days UFH/LMWH therapy in acute VTE ...
Here - Molecular Graphics and Modelling Society
... around one million deaths annually. Previous successes in attempting to eradicate the disease were only short lived due to increased resistance of the mosquito to insecticides, and of the parasite to established drugs such as chloroquine. Computer aided-drug design is an essential part of modern dru ...
... around one million deaths annually. Previous successes in attempting to eradicate the disease were only short lived due to increased resistance of the mosquito to insecticides, and of the parasite to established drugs such as chloroquine. Computer aided-drug design is an essential part of modern dru ...
Full-Text PDF
... occurrence. Despite the prevalence of these anti-coagulants, their employment actually increases the risk of bleeding, brings about the inconvenience of frequent monitoring, interacts with many drugs and foods, as well as has slow onset of action [3], which hinders further clinical application in th ...
... occurrence. Despite the prevalence of these anti-coagulants, their employment actually increases the risk of bleeding, brings about the inconvenience of frequent monitoring, interacts with many drugs and foods, as well as has slow onset of action [3], which hinders further clinical application in th ...
treatment of gastrointestinal ulcers
... Aluminum- or magnesium-containing antacids are considered the most effective with the fewest adverse effects, although they can lead to constipation. Rebound gastric acidity often occurs because of their short halflife. For this reason, antacids are no longer routinely used. Sucralfate (dogs: 0 ...
... Aluminum- or magnesium-containing antacids are considered the most effective with the fewest adverse effects, although they can lead to constipation. Rebound gastric acidity often occurs because of their short halflife. For this reason, antacids are no longer routinely used. Sucralfate (dogs: 0 ...
Enzymes - ISpatula
... so ... we have 3 issues when talking about drug absorption that are dissolution, permeability and stability, and we need to overcome these problem in order to reach the site of action in sufficient concentration and give a response. Regarding affecting permeation, we can do: 1) prodrug, but it is ...
... so ... we have 3 issues when talking about drug absorption that are dissolution, permeability and stability, and we need to overcome these problem in order to reach the site of action in sufficient concentration and give a response. Regarding affecting permeation, we can do: 1) prodrug, but it is ...
Drug design Ligand-based drug design
... For example, if the target is a novel G-protein coupled receptor, compounds will be screened for their ability to inhibit or stimulate that receptor. if the target is a protein kinase, the chemicals will be tested for their ability to inhibit that kinase. Another important function of HTS is to show ...
... For example, if the target is a novel G-protein coupled receptor, compounds will be screened for their ability to inhibit or stimulate that receptor. if the target is a protein kinase, the chemicals will be tested for their ability to inhibit that kinase. Another important function of HTS is to show ...
Lecture 7 - Antidepressants new 11-12
... Metabolism: P450 then conjugation They are enzyme inhibitors Weak inhibitors < Sertraline, Citalopram interaction Strong inhibitors > Fluoxetine, Paroxetine metabolism of TCA, neuroleptic, some antiarrhythmic, β-blockers. Primarily excreted through kidney; not paroxetine & sertraline under ...
... Metabolism: P450 then conjugation They are enzyme inhibitors Weak inhibitors < Sertraline, Citalopram interaction Strong inhibitors > Fluoxetine, Paroxetine metabolism of TCA, neuroleptic, some antiarrhythmic, β-blockers. Primarily excreted through kidney; not paroxetine & sertraline under ...
Suggestion from a pharmaceutical company
... observations coupled with greater convenience for patients and physicians, the Guidelines Committee continues to recommend NOACs over warfarin for nonvalvular AF. There have been no published trials directly comparing the various NOACs, and it is unlikely that any will be conducted in the near futur ...
... observations coupled with greater convenience for patients and physicians, the Guidelines Committee continues to recommend NOACs over warfarin for nonvalvular AF. There have been no published trials directly comparing the various NOACs, and it is unlikely that any will be conducted in the near futur ...
Antiviral and Anti
... a. Side effects: “buffalo hump” (which can sometimes be reversed); similar in appearance to Cushing’s syndrome without the hypercorisolism; incidence is low. XXIII. PERIPHERAL LIPODYSTROPHY SYNDROME [S81] a. Other side effects: fat redistribution, hollow cheeks, visceral fat deposit, breast enlargem ...
... a. Side effects: “buffalo hump” (which can sometimes be reversed); similar in appearance to Cushing’s syndrome without the hypercorisolism; incidence is low. XXIII. PERIPHERAL LIPODYSTROPHY SYNDROME [S81] a. Other side effects: fat redistribution, hollow cheeks, visceral fat deposit, breast enlargem ...
Blood Drugs
... clots Blood coagulation is considered as a series of steps in which plasma inactive enzyme precursors (proenzymes) are transformed into active enzymes Two main pathways have been described for blood coagulation: the intrinsic and the extrinsic pathways ...
... clots Blood coagulation is considered as a series of steps in which plasma inactive enzyme precursors (proenzymes) are transformed into active enzymes Two main pathways have been described for blood coagulation: the intrinsic and the extrinsic pathways ...
Pathophysiology of Thrombosis
... when activated by exposure of the blood to tissue factor released from damaged arterial wall tissue, converts to thrombin. Thrombin in turn converts fibrinogen to fibrin. ...
... when activated by exposure of the blood to tissue factor released from damaged arterial wall tissue, converts to thrombin. Thrombin in turn converts fibrinogen to fibrin. ...
Dabigatran
... 6. INR validated for warfarin relation to bleeding risk 7. Point-of-care testing 8. Rapid turnaround genetic testing ...
... 6. INR validated for warfarin relation to bleeding risk 7. Point-of-care testing 8. Rapid turnaround genetic testing ...
Docking and Drug Design
... • Ligands that bind to a specific protein • Either increase its activity (an agonist) or decrease/block its activity (an antagonist) • Many problems… solubility, stability, selectivity • Most drugs are not very selective… side effects • Rational drug design… exploit structure of the protein and ...
... • Ligands that bind to a specific protein • Either increase its activity (an agonist) or decrease/block its activity (an antagonist) • Many problems… solubility, stability, selectivity • Most drugs are not very selective… side effects • Rational drug design… exploit structure of the protein and ...
Hydrogen Bonding: The Last Mystery in Drug Design?
... The influence of replacing an NH ··· O = C hydrogen bond has been extensively studied in a series of thermolysin inhibitors (Fig. 6). The replacement of the -NH- group of the ligands by –O– reduces binding affinities by a factor of 1 000, which has been explained by the lack of the NH ··· O = C hydr ...
... The influence of replacing an NH ··· O = C hydrogen bond has been extensively studied in a series of thermolysin inhibitors (Fig. 6). The replacement of the -NH- group of the ligands by –O– reduces binding affinities by a factor of 1 000, which has been explained by the lack of the NH ··· O = C hydr ...
Principles of Structure-Based Design
... For example the SB203580 molecule has a Ki of 100 nM on the protein kinase p38. However the molecule looses its activity if residue Thr-106 is mutated by Met-106. The same molecule is entirely inactive on the kinase ERK2, however if the residue Glu105 of the protein is mutated by Thr-105, the Ki o ...
... For example the SB203580 molecule has a Ki of 100 nM on the protein kinase p38. However the molecule looses its activity if residue Thr-106 is mutated by Met-106. The same molecule is entirely inactive on the kinase ERK2, however if the residue Glu105 of the protein is mutated by Thr-105, the Ki o ...